Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label 3K3A-APC trial in amyotrophic lateral sclerosis
ACTRN12621000864820Phase 2Completed
- Sponsor
- Macquarie University
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of 3K3A-APC in amyotrophic lateral sclerosis (ALS) and motor neuron disease (MND) (2 cohorts), sponsored by Macquarie University. Primary endpoints: Composite safety assessment and Microglial activation in motor cortex. Started Nov 2021; status: completed.
02
Drugs
3K3A-APC
03
Conditions
amyotrophic lateral sclerosis (ALS)motor neuron disease (MND)
Beyond the preview
Go deeper on ACTRN12621000864820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000864820.